Corporate Profile

Syndax Pharmaceuticals is a commercial stage biopharmaceutical company developing an innovative pipeline of cancer therapies. Highlights of the Company's pipeline include revumenib a highly selective menin inhibitor, and Niktimvo™ (axatilimab-csfr), a monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor. Syndax is working to unlock the full potential of its pipeline and is conducting several clinical trials across the continuum of treatment for both revumenib and Niktimvo. Syndax corporate headquarters are in Waltham, MA.

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Recent Events

Niktimvo™ (axatilimab-csfr) FDA Approval Conference Call

08.14.24 / 6:00 PM EDT

Syndax Second Quarter 2024 Conference Call

08.01.24 / 4:30 PM EDT

Goldman Sachs 45th Annual Global Healthcare Conference

06.12.24 / 8:40 AM EDT

Sign Up for Email Alerts

Sign-up to automatically receive Syndax financial information by email.
Two people holding hands